Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Novoeight® (antihemophilic factor, recombinant) logo
Important Safety Information | Patient Site
Prescribing Information
  • About Novoeight®
  • Efficacy & Safety
  • Dosing & Administration
  • Cost & Coverage
Novoeight® (antihemophilic factor, recombinant) logo

For on-demand bleed control, surgery and routine prophylaxis in adults and children with hemophilia A.

Prescribing Information
Important Safety Information | Patient Site

An rFVIII designed for portability

Peter lives with hemophilia A.

For patients with hemophilia A, disease management often depends on choosing a treatment that fits into their daily lives.


rFVIII SHL and EHL comparison guidea,b

rFVIII SHL and EHL Comparison Guide

SHL=standard half-life; EHL=extended half-life.
The above table is not intended to compare the safety or efficacy of any of the products.
aDoes not include the EHL Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei].
bData current as of March 4, 2022.

Novoeight® is the ONLY SHL rFVIII with stability up to 104˚F for up to 3 months.1-11,c

cCompared with other selected rFVIII SHL and EHL products.

Novoeight® Professional Brochure
PDF
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Novoeight® Professional Brochure
A reference on Novoeight®, including how its temperature stability may be appropriate for your patients.
Download
Prescribing Information | Important Safety Information

Looking for an rFVIII with extended half-life?

With one proven starting prophylactic dose,d Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] can deliver high trough levels and a low median ABR for adolescent and adult patients.12,e

Explore Esperoct®

Please click here for Esperoct® Prescribing Information and see Important Safety Information at the bottom of the page.

ABR=annualized bleed rate.
d50 IU/kg every 4 days. Regimen can be individually tailored to less or more frequent dosing based on bleeding episodes.12
eIn a phase 3, open-label study, safety, efficacy, and pharmacokinetics (PK) of Esperoct® were evaluated in PTPs aged ≥12 years with severe hemophilia A. Single-dose PK studies were performed in 42 adults after receiving Esperoct® 50 IU/kg; 175 PTPs received routine prophylaxis (50 IU/kg Q4D) for 76 weeks and 12 adults elected to be treated on demand during the main phase. Treatment-requiring bleeds were reported by patients through diaries. Mean trough levels for adults (age ≥18 years) were 3.0 IU/dL and for adolescents (12 to less than 18 years) were 2.7 IU/dL.12,13

Selected Important Safety Information for Novoeight®

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment

Indications and Usage

Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Novoeight® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment
  • Development of activity-neutralizing antibodies (inhibitors) may occur. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight® in PUPs. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors

Adverse Reactions

  • The most frequently reported adverse reactions (≥1%) were inhibitors in Previously Untreated Patients (PUPs), injection site reactions, and pyrexia.

Please click here for Novoeight® Prescribing Information.

Selected Important Safety Information for Esperoct®

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained

Adverse Reactions

  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions

Please click here for Esperoct® Prescribing Information.

References

  1. Novoeight [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2020. 
  2. Adynovate® [package insert]. Westlake Village, CA: Baxalta US Inc., 2021. 
  3. Advate® [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2018. 
  4. Afstyla® [package insert]. Kankakee, IL: CSL Behring LLC; 2021. 
  5. Eloctate™ [package insert]. Cambridge, MA: Biogen Idec Inc.; 2020. 
  6. Jivi® [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2018. 
  7. Kogenate® [package insert]. Tarrytown, NY: Bayer HealthCare LLC; 2019. 
  8. Kovaltry® [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2021. 
  9. Nuwiq® [package insert]. Hoboken, NJ: Octapharma USA, Inc.; 2020. 
  10. Recombinate® [package insert]. Westlake Village, CA: Baxalta US Inc.; 2018. 
  11. Xyntha® [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2020. 
  12. Esperoct [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2019. 
  13. Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A. Thromb Haemost. 2017;117(2):252-261.
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support

Novoeight® and Esperoct® are registered trademarks and novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2022 Novo Nordisk All rights reserved. US22NEGT00001 July 2022

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials